Clinical trial
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid…
NCT00322608 · Nereus Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00322608 |
|---|---|
| Title | Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma |
| Official title | Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma |
| Lead sponsor | Nereus Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | NPI-2358 |
| Enrollment | 35 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | May 8, 2006 |
| Last update posted | Jan 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: